广告
加载中

一季度融资38亿元 中国脑机产业走到哪一步了?

吕哲彤 2026-06-17 16:48
吕哲彤 2026/06/17 16:48

邦小白快读

EN
全文速览

本文梳理了2026年上半年国内脑机接口产业的最新核心进展,普通读者可获得以下关键干货:

1. 产业整体已经从实验室前沿概念逐步转向可落地商用产品,资本加速入场,今年一季度国内脑机领域融资总额达38亿元,已经超过2024年全年,投资逻辑从炒概念转向看企业落地能力,目前已有博睿康冲击“脑机接口第一股”,暖芯迦完成国内首例高分辨率视觉脑机GCP临床试验,阿里腾讯共同投资布局国内脑机企业。

2. 面向普通消费者的产品已经开始推出,非侵入式脑机接口因安全无创,更适合消费场景,国内已有可实现专注力训练、情绪调节、压力舒缓的脑机头环,海外也推出了睡眠监测、女性经期健康相关的消费产品。

3. 目前脑机接口还未实现大规模商用,产品长期安全性仍在积累验证,普通消费者可保持关注,不必盲目跟风尝试小众未合规产品。

当前国内脑机接口产业处于从实验室技术向市场化产品转型的拐点,品牌商可把握以下行业机会与方向:

1. 产品研发方向:医疗端侵入式脑机已经有全球首款三类医疗器械获批上市,聚焦功能重建与医疗康复领域,已经打通合规路径;消费端非侵入式脑机因容易被大众接受,更具增长潜力,可布局睡眠监测、情绪管理、专注力训练、女性健康等热门场景。

2. 合规与资本层面:当前投资逻辑已经转向落地与产业化能力,国家已经出台脑机接口相关国家标准,还筹建了专门的标准化工作组,产品注册审评流程逐步规范,品牌商要提前布局符合标准的产品研发,积累临床数据才能获得资本认可。

3. 竞争层面:当前全球竞争加剧,海外已经推出多款消费级产品,国内全产业链都有新品首发,品牌商可突出自主创新优势抢占市场。

当前脑机接口产业处于早期增长阶段,卖家可把握以下机会,同时注意相关风险:

1. 市场机会:国内脑机产业已经完成从概念到可申报、可检验、可定价的初步闭环,政策端出台了统一国家标准,还筹建了专门的标准化工作组,合规路径越来越清晰;消费端需求已经逐步显现,非侵入式产品可覆盖大众日常的专注力提升、情绪调节、睡眠健康、女性健康等多个场景,目前市场供给较少,存在明显增长空间;资本加速入场,头部企业加速产业化落地,有大量品牌合作、分销代理的机会。

2. 风险提示:目前产业距离大规模商用仍有距离,已获批医疗产品适应症较窄,长期安全性数据尚未积累完全,医保支付也未全面覆盖,全球竞争激烈,入场需优先选择有合规资质、成熟临床数据的企业合作,规避概念炒作带来的风险。

国内脑机接口进入产品化加速阶段,给工厂带来了新的商业机会,也带来了转型启示:

1. 产品生产与设计需求:当前脑机接口已经覆盖从科研、医疗到消费的全产业链,不同类型产品对生产设计有不同要求:侵入式医疗脑机产品需要高精度微型器件的精密生产能力,对半导体加工技术要求高;非侵入式消费级脑机产品需要轻量化硬件的设计生产能力,满足穿戴设备的使用需求。

2. 商业机会:当前头部企业都在推进产业化布局,博睿康IPO拟投入4.1亿元用于脑机接口产业化建设,暖芯迦也在推进产品临床与技术迭代,互联网大厂也纷纷布局,给工厂带来了大量配套生产、代加工的合作机会。

3. 转型启示:新兴产业技术迭代快,对产品合规性要求高,工厂需要加快数字化升级,紧跟行业标准化要求,对接产业端需求才能切入新赛道。

当前国内脑机接口产业处于从概念到产品化的关键拐点,给服务商带来了新的市场机会,核心信息如下:

1. 行业发展趋势:资本加速入场,一季度融资额超去年全年,产品化进程加快,应用覆盖医疗康复、消费穿戴等多个领域,国家也出台了相关标准,筹建了标准化工作组,产业化会在未来几年加速推进,服务商拥有广阔的市场空间。

2. 客户核心痛点:脑机企业多为科技型创业企业,普遍对合规注册流程不熟悉,需要专业的辅导服务;多数企业在推进产业化过程中,有融资对接、产能扩张的需求;消费级脑机企业面向C端,需要渠道搭建、品牌推广、用户教育相关的服务。

3. 可布局的解决方案:服务商可针对性推出脑机企业注册申报辅导、合规咨询服务,对接资本的投融资对接服务,以及面向消费端产品的营销推广、渠道运营服务,贴合企业需求。

脑机接口产业的快速发展,给平台带来了新的发展机遇,平台可从以下方向布局,同时做好风险规避:

1. 行业需求:当前脑机企业正从实验室走向产业化,需要平台提供产业孵化、投融资对接、合规资源对接等服务;消费级脑机产品推出后,需要销售渠道、流量支持、用户运营等相关支持,市场需求明确。

2. 可布局的方向:平台可开设脑机产业专属招商通道,引入拥有合规资质、成熟临床进展的医疗和消费类脑机企业,针对产业端企业提供孵化、合规资源对接服务,针对消费端企业提供流量扶持,帮助教育市场,培育新的增长品类。

3. 风险规避:当前脑机产品长期安全性仍待验证,仍有部分企业存在概念炒作的情况,平台要严格审核企业资质和产品合规性,要求企业明确标注产品适用范围,杜绝虚假宣传,规避监管风险。

2026年国内脑机接口产业出现多个标志性事件,呈现诸多新动向,也存在很多值得深入研究的新问题:

1. 产业新动向:资本层面,今年一季度国内脑机领域融资总额达38亿元,超过2024年全年,投资逻辑从早期的“看概念、卡位置”转向“看落地、看产业化能力”,博睿康冲击科创板IPO有望成为国内“脑机接口第一股”,头部企业获得阿里腾讯等互联网大厂投资;产品层面,医疗端全球首个侵入式脑机三类医疗器械获批上市,临床取得重大突破,消费端全产业链新品首发,应用场景向日常生活拓展;政策层面,国家出台脑机接口相关国家标准,筹建专门的标准化工作组,产业化路径逐步清晰。

2. 待研究的方向:如何拓展现有产品适应症、积累长期安全性数据、推动医保全面覆盖;如何平衡技术研发与商业化落地,构建可持续的商业模式;如何应对全球日益激烈的竞争,提升国内企业核心竞争力,都是值得深入研究的课题。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article summarizes the latest core developments in China's domestic brain-computer interface (BCI) industry in the first half of 2026, with key takeaways for general readers:

1. The industry has gradually shifted from cutting-edge laboratory concepts to commercially viable products, with capital accelerating its inflow. In the first quarter of 2026, total financing in China's BCI sector reached 3.8 billion yuan, exceeding the full-year total of 2024. Investment logic has shifted from concept speculation to evaluating enterprises' commercialization capabilities. Currently, Borun is competing to become the "first BCI stock" via IPO, NEXCHIP completed China's first GCP clinical trial for high-resolution visual BCI, and Alibaba and Tencent have jointly invested in domestic BCI companies.

2. BCI products targeting general consumers have already launched. Non-invasive BCI, due to its safety and non-invasiveness, is more suitable for consumer scenarios. Domestic companies have released BCI headbands that enable focus training, emotion regulation and stress relief, while overseas firms have launched consumer products for sleep monitoring and women's menstrual health management.

3. Large-scale commercialization of BCI has not yet been achieved, and long-term product safety is still being verified. General readers can follow industry developments, but should not blindly try niche, non-compliant products.

China's BCI industry is currently at an inflection point, transitioning from laboratory technology to market-ready products. For brand owners, here are key industry opportunities and directions:

1. Product R&D direction: On the medical side, the world's first Class III invasive BCI medical device has been approved for marketing, focused on functional reconstruction and medical rehabilitation, with a compliance pathway already established. On the consumer side, non-invasive BCI has greater growth potential as it is more readily accepted by the public, and brands can explore high-demand scenarios including sleep monitoring, emotion management, focus training and women's health.

2. Compliance and capital: Investment logic has now shifted to commercialization and industrialization capabilities. China has released national standards for BCI and established a dedicated standardization working group, gradually standardizing product review and registration processes. Brands should start developing standards-aligned products early and accumulate clinical data to gain capital recognition.

3. Competition: Global competition is intensifying. Overseas players have launched multiple consumer BCI products, while new products are debuting across China's entire BCI industry chain. Brands can seize market share by highlighting their independent innovation advantages.

The BCI industry is currently in an early growth stage. Sellers can seize the following opportunities while paying attention to associated risks:

1. Market opportunities: China's BCI industry has completed a preliminary closed loop from concept to product application, featuring declarable, testable and commercially viable offerings. Policymakers have released unified national standards and established a dedicated standardization working group, making compliance pathways increasingly clear. Consumer demand is gradually emerging: non-invasive BCI products can cover multiple daily scenarios including focus improvement, emotion regulation, sleep health and women's health, and current market supply remains limited, leaving significant room for growth. With capital accelerating inflows and leading enterprises speeding up commercialization, there are abundant opportunities for brand cooperation and distribution agency.

2. Risk warnings: The industry is still far from large-scale commercialization. Approved medical products have narrow indications, full long-term safety data has not yet been accumulated, and medical insurance coverage is not comprehensive. Global competition is also fierce. New entrants should prioritize partnering with enterprises that hold valid compliance qualifications and mature clinical data, to avoid risks from concept speculation.

China's BCI industry has entered a phase of accelerated product development, bringing new business opportunities and transformation insights for manufacturing factories:

1. Product design and production requirements: BCI now covers the entire industrial chain from scientific research and medical use to consumer applications, and different product types have different production and design requirements: Invasive medical BCI products require precision manufacturing capabilities for high-precision micro devices, with high requirements for semiconductor processing technology. Non-invasive consumer BCI products require design and manufacturing capabilities for lightweight hardware to meet the needs of wearable devices.

2. Business opportunities: Leading domestic BCI players are all advancing industrial layout. Borun plans to invest 410 million yuan in its IPO proceeds for BCI industrialization construction, NEXCHIP is advancing product clinical trials and technology iteration, and major Chinese internet giants have also entered the space, bringing abundant opportunities for supporting production and OEM cooperation for factories.

3. Transformation insights: Emerging industries see rapid technology iteration and high requirements for product compliance. Factories need to accelerate digital upgrading, keep up with industry standard requirements, and align with industrial demand to enter this new track.

China's BCI industry is currently at a critical inflection point from concept to productization, bringing new market opportunities for service providers. Key insights are as follows:

1. Industry development trend: Capital is accelerating into the sector, with Q1 2026 financing exceeding the full year of 2024. Product development is accelerating, with applications covering medical rehabilitation, consumer wearables and other fields. The Chinese government has released relevant national standards and established a standardization working group, and industrialization will accelerate in the coming years, creating broad market space for service providers.

2. Core client pain points: Most BCI companies are technology-focused startups that are generally unfamiliar with compliance and registration processes, and need professional consulting and guidance services. Most enterprises also have demands for financing connection and capacity expansion when advancing industrialization. Consumer-facing BCI companies require services related to channel building, brand promotion and user education.

3. Solutions to explore: Service providers can launch targeted offerings for BCI enterprises, including registration application guidance and compliance consulting, investment and financing connection services, as well as marketing promotion and channel operation services for consumer products, to meet enterprises' core demands.

The rapid development of the BCI industry brings new development opportunities for industry platforms. Platforms can layout along the following directions while managing risks effectively:

1. Industry demand: BCI enterprises are currently moving from laboratories to industrialization, and need platforms to provide services including industrial incubation, investment and financing connection, and compliance resource matching. After launch, consumer BCI products need support for sales channels, traffic and user operation, so market demand is clear.

2. Layout directions: Platforms can open dedicated investment attraction channels for the BCI industry, introduce compliant medical and consumer BCI enterprises with mature clinical progress, provide incubation and compliance resource matching services for industrial clients, and offer traffic support for consumer-facing enterprises to help educate the market and cultivate new growth categories.

3. Risk mitigation: Long-term safety of BCI products remains to be verified, and some enterprises still engage in concept speculation. Platforms must strictly review enterprise qualifications and product compliance, require enterprises to clearly mark product scope of application, crack down on false advertising, and avoid regulatory risks.

China's BCI industry saw multiple landmark events and new trends in 2026, with many new questions worthy of in-depth research:

1. New industry trends: On the capital side, total financing in China's BCI sector reached 3.8 billion yuan in Q1 2026, exceeding the full-year total of 2024. Investment logic has shifted from early-stage "betting on concepts and securing positions" to "evaluating commercialization progress and industrialization capabilities". Borun's upcoming STAR Market IPO is set to become China's first publicly listed pure BCI company, and leading domestic BCI players have received investment from internet giants including Alibaba and Tencent. On the product side, the world's first Class III invasive BCI medical device has been approved for marketing, marking a major clinical breakthrough, while new consumer BCI products have debuted across China's entire industrial chain, expanding application scenarios into daily life. On the policy side, China has released national BCI standards and established a dedicated standardization working group, gradually clarifying the path for industrialization.

2. Directions for future research: Key topics worthy of in-depth research include: how to expand indications for existing products, accumulate long-term safety data and promote full medical insurance coverage; how to balance technology R&D and commercialization to build sustainable business models; and how to respond to increasingly intense global competition and improve the core competitiveness of Chinese BCI enterprises.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】2026年6月,国内脑机接口领域接连出现多个标志性事件。

6月8日,暖芯迦宣布我国首例高分辨率视觉脑机GCP临床试验取得成功,一名失明二十年的患者在术后初步恢复功能性视力;6月10日,5款国产脑机接口创新产品在上交会首发,覆盖从科研到消费的全产业链;6月11日,博睿康科创板IPO获受理,被视为“脑机接口第一股”的有力竞争者。

资本层面,据上证报统计,一季度国内脑机接口领域融资总额约38亿元,已超过去年全年。

埃隆·马斯克在2016年创立Neuralink带火了脑机接口技术,Neuralink通过植入电极实现人脑与外部设备交互,今年5月6日,该公司宣布正在研发一种能够到达大脑任何区域的手术机器人,目标是开发通用的神经接口,以帮助解决与大脑相关的疾病。不过,该产品尚未获得FDA认证。

整体上,脑机接口正在经历从实验室技术向可注册、可收费、可上市产品的关键转变。

01 资本加速入场 概念逐步落地

据上证报统计,2026年第一季度,中国脑机接口领域共发生17起融资事件,融资总额约38亿元,单季规模已超2024年全年。据上证报报道,在5月举行的全国脑机接口科技与产业融合创新大会上,多位专家表示,投资逻辑正从“看概念,卡位置”转向“看落地,看产业化能力”。

6月11日,上交所官网显示,博睿康科创板IPO审核状态变更为“已受理”。由于当前A股市场虽存在脑机接口概念股,但尚无主营业务聚焦脑机接口的上市公司,博睿康如能顺利上市,或将成为“脑机接口第一股”。

据博睿康招股书披露,此次IPO拟融资金额为25亿元。其中,15.4亿用于脑机接口研发项目,4.1亿用于脑机接口产业化建设项目,5.5亿用于补充流动资金。

天眼查显示,此前博睿康已完成多轮融资,投资方包括红杉中国、松禾资本、达晨财智、百度风投、中关村发展等知名机构。该公司最新一轮融资为2025年12月的E轮融资。据招商局中国基金公告,深圳市天正投资有限公司(招商局中国基金全资附属公司)斥资1500万元参与博睿康E轮融资,于2025年11月完成出资。

临床应用方面,博睿康已取得进展。今年3月,国家药监局批准博睿康植入式脑机接口手部运动功能代偿系统创新产品注册申请。据称,这是全球首个植入式脑机接口三类医疗器械正式获批上市,标志着国际首个侵入式脑机接口医疗器械进入临床应用阶段。

另一家具有代表性的公司是暖芯迦电子科技有限公司(简称“暖芯迦”,英文Nanochap)。据其官网介绍,该公司成立于2014年,专门从事神经接口与生物传感研发的技术型企业,已有17年以上的研究和开发资历,团队核心成员均来自澳大利亚墨尔本大学神经工程中心与全球半导体大厂,多数成员具备电子工程和生物医学工程双学位。

5月6日,暖芯迦宣布完成3亿元战略融资,由产业投资机构与君联资本联合领投,丰年资本超额追投,广发信德和财通资本跟投,资金将重点用于视觉脑机接口产品的临床试验推进和核心技术迭代。

6月8日,暖芯迦宣布我国首例高分辨率视觉脑机GCP临床试验取得成功。据称,一名失明二十年的患者在术后开机调试的第二天就能识别字母,创造了视觉重建的最快记录。

与此同时,互联网大厂也在布局脑机接口。6月9日,天眼查App显示,植入式脑机接口企业阶梯医疗完成工商变更,新增股东包括阿里巴巴旗下杭州灏月企业管理有限公司、腾讯旗下上海启善投资有限公司,注册资本由100万增至约300.6万元。这是阿里与腾讯在脑机接口领域的罕见“同框”。

02 产品化进程加速 标准化同步跟进

据科普时报报道,根据北京航空总医院脑机接口诊疗中心副主任医师刘东升的介绍,脑机接口根据侵入程度不同,可分为三类:

非侵入式:将电极贴在头皮外,安全无创但信号精度有限;

侵入式:微型器件直接植入大脑皮层,信号清晰稳定,聚焦功能重建与医疗康复领域;

半侵入式:将电极置于大脑表面或颅骨下,是在信号质量和手术创伤间寻求平衡。

日前,脑机接口产品化进程加速,不仅在侵入式和医疗应用领域取得进展,也在拓宽应用场景,快速向非侵入式、消费级和更多日常生活领域扩展。

据证券时报报道,6月11日开幕的第十二届上交会上,5款国产脑机接口创新产品实现首发,完整覆盖从脑科学基础研究、高端医疗设备、康复康养到大众日常消费的全产业链条,代表了中国脑机产业自主创新的最新成果。

如果说脑机接口用在医疗领域是为了“补偿”,那么对于消费级场景而言,它的作用就在于“监测”和“增强”。从普通人的角度来看,非侵入式脑机接口心理上更容易接受,因此更具消费级应用潜力。

当前,海外已有多款将非侵入式脑机接口作为卖点的消费级智能穿戴设备,聚焦睡眠监测、情绪管理等场景。比如Muse曾推出多款智能头带,以EEG(脑电图)监测为核心,功能覆盖睡眠监测、注意力管理、压力管理。

Muse的两款智能头带 来源:Muse官网

今年5月,智子银河在美国硅谷发布智能发箍UnaBand,聚焦女性经期健康。该公司成立于2026年,总裁黄河龙博士毕业于中国科学技术大学,具备生殖学学术积累,其团队成员背景覆盖脑科学、认知神经等领域。

近期,国内也有消费级脑机接口产品发布。6月6日,华南脑控(广东)智能科技有限公司推出消费级智能穿戴产品宁脑·AI灵犀脑机接口头环。据称,该产品在硬件方面采用轻量化设计,软件层面围绕大众日常学习、生活场景进行研发,可实现专注力训练、情绪调节、压力舒缓、正念引导等。

但脑机接口的商业化前提是:技术被证明在人体上安全、有效。一项新兴技术要进入医疗体系和消费级场景,标准化不可或缺。

今年4月,市场监管总局(国家标准委)批准发布一批重要国家标准,其中涉及脑机接口、智能网联汽车、半导体器件等18项新兴领域国家标准。这意味着脑机接口产品在技术指标、安全要求、测试方法等方面开始有统一依据。

5月6日,据央视新闻报道,市场监管总局批准筹建全国智能化医疗器械标准化工作组,由国家药监局负责管理。该工作组负责的领域包括人工智能医疗器械、医用机器人、脑机接口医疗器械以及融合技术类医疗器械等。

随着标准化工作组的成立,脑机接口相关行业标准、团体标准的制定和修订将进一步加速,产品注册和审评流程将更加规范。

03 产业拐点已至 但挑战仍在

从博睿康冲刺IPO,到暖芯迦临床成功,再到国家标准发布和标准化工作组筹建,脑机接口在中国完成了从“前沿概念”到“可申报、可检验、可定价”的初步闭环。资本市场的反应也表明,投资者不再满足于押注赛道,而是更看重企业的临床进度、注册能力和产业化路径。

但现阶段来看,脑机接口距离大规模商用仍有距离。已获批产品的适应症仍较窄,长期安全性数据有待积累,医保支付体系尚未全面覆盖。Neuralink等国际企业的进展也提醒市场,这一领域的全球竞争仍在加剧。

总体而言,2026年上半年密集出现的IPO、临床数据和标准化动作,共同指向一个趋势:脑机接口正在从少数实验室的“样品”,逐步转变为医院、消费者有可能接触到的“产品”。接下来的关键,是这些产品能否真正进入临床路径、真实场景,获得医生、患者、大众的认可,并在标准体系下实现规模化生产。


亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

文章来源:亿邦动力

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0